Biotech Investments

Chinese biotech Kelun-Biotech is advancing 30+ oncology candidates including novel antibody-drug conjugates through late-stage trials, joining Pfizer, Regeneron, and BioNTech in a concentrated 2026-2027 regulatory approval cycle. The pipeline acceleration spans targeted therapies across multiple cancer types, with ADC platforms emerging as a key competitive battleground. Regulatory milestones clustering in the next 18 months signal heightened valuation pressure across the sector.

Kyntra Bio, the rebranded FibroGen, concentrates 70% of its enterprise value in FG-3246, an antibody-drug conjugate for prostate cancer. The oncology candidate faces medium-probability trial failure or FDA rejection that could wipe out investor capital. Single-asset biotech firms show 40% higher volatility than diversified pharma peers.